Pazoo (PZOO) 10-K 14 May 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Jun. 30, 2014
Document and Entity Information:
Entity Registrant Name	Pazoo, Inc.
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Entity Central Index Key	1533427
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		107,765,750
Entity Public Float		$1,077,657
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2014		Dec. 31, 2013
Current assets:
Cash and cash equivalents	$733,637		$35,848
Accounts receivable	87,949		33,461
Stock subscription receivable	18,253
Inventories	2,668		4,129
Prepaid expenses	6,181		1,911
Total current assets	848,688		75,349
Total assets	848,688		75,349
Current liabilities:
Accounts payable and accrued liabilities	84,189		64,846
Loans payable	3,000		3,000
Interest payable	46,862
Convertible debt	895,664	[1]	1,849	[2]
Derivative liabilities	2,576,025		172,049
Total current liabilities	3,605,740		241,744
Long-term liabilities:
Long-term portion of convertible debt	28,832	[3]	0	[4]
Total long-term liabilities	28,832
Total liabilities	3,634,572		241,744
Stockholders' deficit
Common stock	193,031		101,410
Convertible preferred stock Series A	1,036		923
Preferred stock Series B	1,187		1,187
Additional paid-in capital	4,438,811		2,250,451
Accumulated deficit	-7,419,949		-2,520,366
Total stockholders' deficit	-2,785,884		-166,395
Total liabilities and stockholders' deficit	$848,688		$75,349
[1]	Net of unamortized discounts of $413,898.
[2]	Net of unamortized discounts of $48,151.
[3]	Net of unamortized discounts of $783,668.
[4]	Net of unamortized discounts of $0.

Statement_of_Financial_Positio

Statement of Financial Position - Parenthetical (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, Par Value	$0.00
Common Stock, Par Value	$0.00	$0.00
Common Stock, Shares Authorized	980,000,000	980,000,000
Common Stock, Shares Issued	193,030,398	101,409,500
Common Stock, Shares Outstanding	193,030,398	101,409,500
Warrants Issued	7,000,000	2,400,000
Warrants Outstanding	7,000,000	2,400,000
Preferred Stock Series A
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	1,036,394	923,394
Preferred Stock, Shares Outstanding	1,036,394	923,394
Preferred Stock Series B
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	2,500,000	2,500,000
Preferred Stock, Shares Issued	1,187,500	1,187,500
Preferred Stock, Shares Outstanding	1,187,500	1,187,500
Preferred Stock Series C
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	7,500,000	7,500,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Advertising sales	$111,036	$42,824
Merchandise sales - revenues	251	9,989
Total revenues	111,287	52,813
Cost of goods sold
Merchandise sales - cost	541	8,977
Total cost of goods sold	541	8,977
Gross profit	110,746	43,836
Operating expenses:
Selling, general and administrative expenses	1,639,228	418,778
Bad debt expense		60
Professional fees	642,740	111,394
Website setup	197,089	49,220
Total operating expenses	2,479,057	579,452
Loss from operations	-2,368,311	-535,616
Loss on derivative liabilities	-1,292,419	-122,049
Loss on impairment of equity method investment	-542,780
Interest expense	-696,073	-25
Net loss	-4,899,583	-657,690
Series A preferred stock dividends	-105,079	-66,701
Net loss attributable to common stockholders	($5,004,662)	($724,391)
Net loss per common share - basic and diluted	($0.04)	($0.01)
Weighted average common shares outstanding - basic and diluted	129,834,534	85,655,534

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($4,899,583)	($657,690)
Common stock issued for services	1,061,358	96,128
Preferred stock issued for services	54,650
Loss on derivative liabilities	1,292,419	122,049
Convertible debt issued for rent expense	16,601
Loss on impairment of equity method investment	542,780
Amortization of debt discounts	635,273	1,849
Bad debt expense		60
Accounts receivable (increase/decrease)	-54,488	11,539
Inventory (increase/decrease)	1,461	2,679
Prepaid expenses and other current assets (increase/decrease)	-4,270	1,625
Accounts payable and accrued liabilities (increase/decrease)	19,343	48,686
Interest payable	60,749
Net cash used in operating activities	-1,273,707	-373,075
Cash flows from investing activities:
Investment in equity method investee	-542,780
Net cash used in investing activities	-542,780
Cash flows from financing activities:
Borrowings on loans payable		33,500
Borrowings on convertible note, net of original issue discounts	2,297,200	50,000
Cash payments on convertible debt	-240,000
Proceeds from sale of common stock	77,076
Proceeds from exercise of Series A preferred warrants	40,000
Proceeds from sale of Series A preferred stock and warrants	340,000	194,867
Net cash provided by financing activities	2,514,276	278,367
Net increase (decrease) in cash and cash equivalents	697,789	-94,708
Cash and cash equivalents beginning of period	35,848	130,556
Cash and cash equivalents end of period	$733,637	$35,848

STATEMENTS_OF_STOCKHOLDERS_EQU

STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Common Stock	Series A Preferred Stock	Series B Preferred Stock	Additional Paid-In Capital	Accumulated Deficit
Balance, Value at Dec. 31, 2012	$145,167	$72,142	$554	$1,375	$1,867,071	($1,795,975)
Balance, Shares at Dec. 31, 2012		72,142,000	554,281	1,375,000
Common shares issued for services, Value	96,128	2,518			93,610
Common shares issued for services, Shares		2,517,500
Conversion of Preferred Stock to Common Stock, Value		28,750	-288		-28,462
Conversion of Preferred Stock to Common Stock, Shares		28,750,000	-287,500
Profit (loss)	-657,690					-657,690
Balance, Value at Dec. 31, 2013	-166,395	101,410	923	1,187	2,250,451	-2,520,366
Balance, Shares at Dec. 31, 2013	101,409,500	101,409,500	923,394	1,187,500
Common shares issued for services, Value	1,061,358	35,374			1,025,984
Common shares issued for services, Shares		35,374,269
Conversion of Preferred Stock to Common Stock, Value		26,950	-270		-26,680
Conversion of Preferred Stock to Common Stock, Shares		26,950,000	-269,500
Preferred stock and warrants issued for cash, Value	340,000		288		339,712
Common shares issued for subscription receivable, Value	18,253	1,740			16,513
Common shares issued for subscription receivable, Shares		1,739,591
Common shares issued for cash, Value	77,076	5,196			71,880
Common shares issued for cash, Shares		5,196,117
Common shares issued for conversion of debt, Value	207,843	21,111			186,732
Common shares issued for conversion of debt, Shares		21,110,921
Common shares issued with debt, Value	35,897	1,250			34,647
Common shares issued with debt, Shares		1,250,000
Resolution of derivative liabilities	445,017				445,017
Profit (loss)	-4,899,583					-4,899,583
Balance, Value at Dec. 31, 2014	($2,785,884)	$193,031	$1,036	$1,187	$4,438,811	($7,419,949)
Balance, Shares at Dec. 31, 2014	193,030,398	193,030,398	1,036,394	1,187,500

Note_1Description_of_Business_

Note 1-Description of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
Note 1-Description of Business and Significant Accounting Policies	Note 1—DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
	Description of Business
	We were incorporated as a C-Corporation in the State of Nevada as IUCSS, Inc. on November 16, 2010 and we established a fiscal year end of December 31. On May 9, 2011, we changed our name to Pazoo, Inc. to take advantage of unique branding and website opportunities. We are a start-up health and wellness social community that has developed its website (www.pazoo.com) to provide information, services, and online products for improvement of everyday living. Our mission is to be 1) a leading social community offering best-in-class health and wellness products for both people and pets; and 2) an important resource for consumers and professionals with diverse information about health and wellness. We have never been party to any bankruptcy, receivership or similar proceeding, nor have we undergone any material reclassification, merger, consolidation, purchase or sale of a significant amount of assets not in the ordinary course of business.
	Use of Estimates
	In accordance with Generally Accepted Accounting Principles (GAAP) the preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.
	On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described at relevant sections in the notes to the financial statements.
	Equity Method Investments
	Equity method investees are all entities over which the Company has significant influence, but not control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights. Investments in equity method investees are accounted for using the equity method of accounting and are initially recognized at cost. As of December 31, 2014, the Company has investments in, MA & Associates, LLC and Harris Lee, LLC which provide the Company with significant influence.
	On April 8, 2014 the Company entered into a Limited Liability Company Membership Interest Purchase Agreement with MA & Associates, LLC (“MA”) under which the Company agreed to acquire a 40% equity interest in MA for two testing locations in exchange for a purchase price of $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock. MA was formed to become a marijuana testing laboratory within the State of Nevada. As set forth in the Purchase Agreement, the Purchase Price is to be paid to MA in accordance with certain milestones including the approval of a State License to become a testing laboratory, laboratory build out milestones, and testing equipment purchases.  In 2014 the Company paid an aggregate of $542,780 of the cash portion of the purchase price consisting of an investment of $542,780. As of December 31, 2014, the Company owned an approximate 22% interest in MA and had the right to appoint one of four Board members of MA. This equity method investment was fully impaired during 2014. In 2015, the Company paid an additional $605,000 of the $2,000,000 cash portion of the purchase price and issued 100,000 of the 150,000 shares to be issued with the remaining shares being issued after the testing laboratory is operational.  A copy of the Purchase Agreement is attached as Exhibit 99.01 to the Form 8-K filed by the Company on April 9, 2014.
	On July 23, 2014, the Company and the MA founders formed Harris Lee Holdings, LLC (“Harris Lee”) of which the Company obtained a 45% equity interest for an initial cash contribution of $45.  On October 24, 2014, the Company agreed to acquire an additional 10% interest in Harris Lee in exchange for 300,000 shares of the Company’s Series C Preferred stock based on a series of milestone events. As of December 31, 2014, the acquisition of this additional 10% interest had not closed. Then on January 13, 2015, the Company agreed to acquire the remaining 45% of Harris Lee in exchange for 450,000 shares of the Company’s Series B Preferred Stock, again issued upon completion of certain milestones.  No construction has commenced on any Harris Lee facility and accordingly no cash has been paid to date.  No shares were issued in 2014. In 2015, based on the milestones, 150,000 shares of Series C Preferred Stock were issued, and all of the 450,000 shares of Series B Preferred Stock were issued.
	The Company recognizes its share of the net income or losses for MA and Harris Lee in the Statements of Operations, after adjustments to align the accounting policies with those of the Company, from the date that significant influence commences until the date that significant influence ceases. When the Company’s share of losses exceeds its interest in an equity method investees, the carrying amount of that interest (including any long-term loans) is reduced to zero and recognition of further losses is discontinued except to the extent that the  Company has incurred legal or constructive obligations or made payments on behalf of the equity method investees. Unrealized gains on transactions between the Company and its equity method investees are eliminated to the extent of the Company’s interest in the equity method investees. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Re-measurement differences of equity stake resulting from gaining control over the investee previously recorded as an equity method investments are recorded under Results related to investments in equity method investees. During the year ended December 31, 2014, aggregate equity method investment losses recognized was zero as it was determined to be nominal.
	During the year ended December 31, 2014, the Company performed an impairment analysis and determined that due to the fact that MA is a start up with no current cash flows; we impaired 100% of the equity method investment resulting in an impairment loss of $542,780 during 2014.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash and cash equivalents and accounts payable. The Company believes that the recorded values of all of its other financial instruments approximate their fair values because of their nature and respective maturity dates or durations. The fair value of our long-term debt is determined by using estimated market prices. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:
	Level 1: Inputs are based on quoted market prices for identical assets or liabilities in active markets at the measurement date.
	Level 2: Inputs include quoted prices for similar assets or liabilities in active markets and/or quoted prices for identical or similar assets or liabilities in markets that are not active near the measurement date.
	Level 3: Inputs include management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value as December 31, 2014 and 2013.
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability – December 31, 2014	$	-	$	-	$	2,576,025	$	2,576,025
	Derivative liability – December 31, 2013	$	-	$	-	$	172,049	$	172,049
	Cash and Cash Equivalents
	We classify all highly liquid instruments with an original maturity of three months or less at the time of purchase as cash equivalents.
	Stock Based Compensation
	Total stock-based compensation recognized during 2014 and 2013 totaled $1,116,008 consisting of 35,374,269 common shares and 15,000 Series A preferred shares and $96,128 consisting of 2,517,500 common shares, respectively.  ASC 718 "Compensation - Stock Compensation" prescribes accounting and reporting standards for all stock-based payments awarded to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, which may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction is recognized as a liability; otherwise, the transaction is recognized as equity.  The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date, the performance completion date, or the contract date.
	Revenue Recognition
	Revenues are recognized when evidence of an agreement exists, the price is fixed or determinable, collectability is reasonably assured and goods have been delivered or services performed.  The Company is paid revenue from various advertising sources.  Typically advertising revenue is based upon the activity reports received from the advertising brokers and revenue is paid in accordance with the broker agreements at varying intervals from 30 to 75 days following the close of the particular advertising period.  The Company recognizes the revenue, and records the accounts receivable, upon receipt of the activity report from the broker.  In the event payment is not received within 120 days of the due date, the Company with classify such amount as an account where collection is doubtful.  At this time the Company has no reason to believe any accounts are not collectible and therefore no allowance for doubtful accounts has been made at this time for any advertising revenue.
	Inventories
	Inventory currently consists predominately of goods purchased from third party suppliers and does not include raw materials. Certain inventory contains expiration dates (“shelf life”) and the efficacy of any product which is held beyond its shelf life may be impaired. Our inventory reserve is zero. The company purchased most inventory in 2011 with very little purchases in 2012 and as such, there are some products that are approaching the end of their shelf life and were written off in 2013 and 2014. Inventory cost is determined using the weighted average cost method.
	Income Taxes
	Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse.
	We have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that we will not realize a future tax benefit, a valuation allowance is established.
	Basic and Diluted Net Loss Per Common Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects, in addition to the weighted average number of common shares, the potential dilution if shares of convertible preferred stock were converted into shares of common stock and a corresponding accrued 5% dividend, unless the effects of such exercises and conversions would have been anti-dilutive.
	Recent Accounting Pronouncements
	The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial condition or results of operations.

Note_2Going_Concern

Note 2-Going Concern	12 Months Ended
	Dec. 31, 2014
Notes
Note 2-Going Concern	Note 2—GOING CONCERN
	During 2014 and 2013, the Company incurred net losses of $4,899,583 and $657,690, respectively. In addition, as of December 31, 2014, the Company had a working capital deficit of $2,757,052. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon our ability to generate sufficient cash flow to meet our obligations on a timely basis and ultimately attain profitability. Management believes that we can alleviate the facts and circumstances which indicate a going concern by expanding our services, expert advice and online products.

Note_3Stockholders_Equity

Note 3-Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Notes
Note 3-Stockholders' Equity	Note 3—STOCKHOLDERS’ EQUITY
	Preferred Stock
	We have authorized 20 million shares of $0.001 par value Preferred Stock. The preferred shares available for issuance are 10,000,000 Series A Convertible Preferred Stock, 2,500,000 Series B Non-convertible Preferred Stock, and 7,500,000 Series C Non-convertible Preferred Stock.
	The Series A Preferred Stock is convertible into ten shares of common stock for each Preferred share at the option of the holder, does not have voting rights and pays a Series A Preferred Stock dividend of 5% annually. The Company amended the Certificate of Designations of the Series A Preferred Stock amending the expiration date to February 1, 2022. The Company shall pay the amount due on the Maturity Date in kind with shares of Common Stock. The number of shares of Common Stock to be issuable to a Holder on the Maturity Date (the “Maturity Shares”) shall be equal to the quotient of (x) the aggregate Liquidation Preference for such Holder’s Shares on the Maturity Date divided by (y) the Conversion Price in effect as of the Maturity Date. On or before the third (3rd) Business Day following the Maturity Date (the “Maturity Share Delivery Date”), the Company must deliver to each Holder the Maturity Shares issuable to such Holder. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to (A) $1,000 per Share held by such Holder, plus (B) a further amount equal to any Dividends accrued but unpaid on such Shares. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be appropriately adjusted for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	The Series B Preferred Stock is non-convertible, does not pay a dividend, and contains voting rights at a ratio of 200 votes for each share of Series B Preferred Stock. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to $0.001 per Share held by such Holder, or such other amount as any Securities Purchase Agreement under which the Shares are issued may provide. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be unaffected for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	The Series C Preferred Stock is non-convertible and has no voting rights, pays a common stock dividend from 2% to 12% annually. The Company amended the Certificate of Designations of the Series C Preferred Stock amending the expiration date for redemption to February 1, 2022. The Company shall pay the amount due on the Maturity Date in kind with shares of Common Stock. The number of shares of Common Stock to be issuable to a Holder on the Maturity Date (the “Maturity Shares”) shall be equal to the quotient of (x) the aggregate Liquidation Preference for such Holder’s Shares on the Maturity Date divided by (y) the Conversion Price in effect as of the Maturity Date. On or before the third (3rd) Business Day following the Maturity Date (the “Maturity Share Delivery Date”), the Company must deliver to each Holder the Maturity Shares issuable to such Holder. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to (A) $0.001per Share held by such Holder, plus (B) a further amount equal to any Dividends accrued but unpaid on such Shares. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be appropriately adjusted for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	In May 2013, we exchanged 136,058 Series A Preferred Stock and 136,058 Series A Preferred stock warrants to Integrated Capital Partners, Inc. (ICPI) for the conversion of $54,423 in loans payable.
	Also, in November 2013, we exchanged 1,774 Series A Preferred Stock and 1,774 Series A Preferred stock warrants to ICPI for $710 in loans payable.
	During 2013, the Company sold an aggregate of 487,168 shares of Series A Preferred Stock and 487,168 Series A Preferred stock warrants for cash proceeds of $194,867.
	In December 2013, we recorded a preferred stock dividend of 31,612 shares of Series A Preferred Stock valued at $66,701 which represents payment of the 5% stated Series A Convertible Preferred Stock dividend (through December 31, 2013).
	In August 2013, 187,500 Series B Preferred shares were sent back to the Company and cancelled for David Cunic, who stepped down as Chairman of the Board in 2012.
	During 2013, 287,500 shares of Series A preferred stock were converted into 28,750,000 common shares.
	Total Series A Preferred shares outstanding as of December 31, 2013 were 923,394.
	On or about March 17, 2014, the Board of Directors voted to affect a 10 for 1 reverse stock split on all outstanding Series A Preferred Stock. All share and per share amounts herein have been retroactively restated to reflect the split.
	On or about April 8, 2014 the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the “Purchase Agreement”) with MA and Associates, LLC (“MA”) whereby the Company will acquire a 40% equity interest in MA in exchange for $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock.  The Company will complete its due diligence by April 30, 2014 and the closing will occur following the Company’s satisfaction of its due diligence.  MA is in the process of setting up two licensed marijuana testing facilities in the State of Nevada. No shares were issued during the year ended December 31, 2014.
	In 2014, The Company sold an aggregate of 287,500 of Series A Preferred Stock and 287,500 Series A preferred stock warrants for cash proceeds of $340,000.
	In 2014, ICPI exercised warrants in the amount of 80,000 Series A Preferred Stock warrants for cash proceeds of $40,000
	In August 2014, 10,000 shares of Series A Preferred Stock was issued to Jordan Stroum as Pazoo’s representative to MA & Associates in Las Vegas, Nevada per the agreement signed July 25, 2014. Series A Preferred Stock converts at a rate of 100:1. The 10,000 Series A Preferred Stock convert into 1,000,000 shares of common stock. The shares were valued at $34,800.
	In October 2014, 5,000 Series A Preferred Stock was issued to Jordan Stroum in exchange for services rendered as Pazoo’s representative to MA & Associates in Las Vegas, Nevada as per the agreement signed July 25, 2014.  Series A Preferred Stock converts at a rate of 100:1.  The 10,000 Series A Preferred Stock convert into 1,000,000 shares of common stock. The shares were valued at $19,850.
	During 2014, 269,500 shares of Series A preferred stock were converted into 26,950,000 common shares.
	Total Series A Preferred shares outstanding as of December 31, 2014 were 1,036,394.
	Common Stock
	Issuances
	In 2013, we issued a total of 2,517,500 common shares to experts who have agreed to be included in the “Our Experts” section of our Company website (www.pazoo.com). Each Expert has executed an expert services contract certain number of shares issued upon signing and further shares earned over the first year of the contract. The total stock compensation expense recorded during 2013 was $96,128. As of December 31, 2013, there were 2,815,000 shares to be issued that will be earned through 2014.
	In April 2013, we cancelled 2,000,000 common shares previously issued to Gotham Capital for an advisory agreement 2012.
	In 2014, we issued a total of 5,196,117 common shares for aggregate cash proceeds of $77,076, in accordance with the put agreements per the equity agreement with Premier Venture Capital dated April 4, 2014.
	In 2014, we issued a total of 1,739,591 common shares for a stock subscription receivable $18,253 which was collected during 2015.
	In 2014, we issued a total of 35,374,269 common shares to consultants and experts who have agreed to be included in the “Our Experts” section of our Company website (www.pazoo.com) as well as certain consultants.  Each expert has executed an expert services contract giving them a certain number of shares issued upon the signing of the agreement and further shares on each anniversary of the contract date. Consultants were used by the Company to increase its marketing, advertising, and awareness. Consultants were issued shares based on individual service contracts. The total stock compensation expense recorded during 2014 was $1,061,358. As of December 31, 2014, there were 5,893,333 shares to be issued that will be earned through 2015.
	In 2014, we issued 1,250,000 common shares with debt valued and recorded as a debt discount at $35,897.
	Conversions
	In 2014, we issued an aggregate of 21,110,921 common shares for the conversion of debt and accrued interest totaling $207,843.
	Warrants
	Simultaneous with the issuance of Series A Preferred Stock in 2013, and under the Investment Agreement May 2013 we issued 623,226 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $0.50, subject to the terms of the warrant agreement between the warrant agent and us. The warrants are exercisable three years from the date of issue. No warrants have been exercised as of December 31, 2013. These warrants had negligible fair value at the time of issuance.
	In connection with a termination and release agreement on or about April 2013, and related to compensation paid to Gotham Capital (Gotham) in 2012, we cancelled 2,000,000 common stock purchase warrants exercisable at an exercise price of $0.01 per share.
	In 2014, ICPI exercised 80,000 Series A Preferred Stock warrants for cash proceeds of $40,000
	In 2014, The Company sold an aggregate of 287,500 of Series A Preferred Stock and 287,500 Series A preferred stock warrants for cash proceeds of $340,000.
	The following table presents the Series A preferred stock warrant activity during 2014 and 2013:
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		200,000	$	7.5
	Granted		623,226	$	0.5
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		287,000		2.18
	Forfeited/canceled		-80,000		0.5
	Exercised		-		-
	Outstanding - December 31, 2014		1,030,226	$	2.23
	Exercisable – December 31, 2014		1,030,226	$	2.23
	The weighted average remaining life of the outstanding Series A preferred stock warrants as of December 31, 2014 and 2013 was 3.26 and 3.92 years, respectively.
	The following table presents the common stock warrant activity during 2014 and 2013:
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		7,000,000	$	0.05
	Granted		-		-
	Forfeited/canceled		-2,000,000		0.05
	Exercised		-		-
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		1,130,470		0.05
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding – December 31, 2014		6,130,470	$	0.05
Exercisable – December 31, 2014		6,130,470	$	0.05
The weighted average remaining life of the outstanding Series A common stock warrants as of December 31, 2014 and 2013 was 0.48 and 1.26 years, respectively.

Note_4Related_Party_Transactio

Note 4-Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes
Note 4-Related Party Transactions	Note 4—RELATED PARTY TRANSACTIONS
	Related Party Transactions
	Steve Basloe has an equity ownership interest in Pazoo and is the Chairman of the Board and the President of Pazoo. He is also the owner of SMB Marketing. SMB Marketing signed a consulting agreement with Pazoo in June 2013 to create strategy and execute against this plan to roll out the design and production of Pazoo.com and the content for Pazoo.com. The agreement is for a term of two years and requires minimum weekly compensation of $1,000. During 2014 and 2013, he received $57,650 and $14,750 for services provided.

Note_5Convertible_Notes

Note 5-Convertible Notes	12 Months Ended
	Dec. 31, 2014
Notes
Note 5-Convertible Notes	Note 5—CONVERTIBLE NOTES
	The following table summarizes the changes in the convertible notes during 2013 and 2014:
		Short Term			Long Term			Total
	Balance as of December 31, 2012	$	-		$	-		$	-
	Cash additions		50,000			-			50,000
	Non-cash additions					-			-
	Cash payments		-			-			-
	Conversions		-			-			-
	Original issue discount		-			-			-
	Total		50,000			-			50,000
	Less:  unamortized discount		(48,151	)		-			(48,151	)
	Balance as of December 31, 2013	$	1,849		$	-		$	1,849
	Cash additions		1,444,700			852,500			2,297,200
	Non-cash additions		16,601			-			16,601
	Cash payments		(240,000	)		-			(240,000	)
	Conversions		(88,400	)		(50,000	)		(138,400	)
	Original issue discount		176,661			10,000			186,661
	Total		1,309,562			812,500			2,122,062
	Less:  unamortized discount		(413,898	)		(783,668	)		(1,197,566	)
	Balance as of December 31, 2014	$	895,664		$	28,832		$	924,496
	On December 4, 2013 the Company entered into a $500,000 Promissory Note with JMJ Financial of which $50,000 is original issue discount. (Attached as Exhibit 99.02 to the Company's Form 8-K filed December 17, 2013).  Under the terms, the Company will receive one or more installments on a periodic basis and will have 90 days for the date of each installment in which to repay the principal amount of the loan and interest. In the event repayment is not made within the 90 day period, JMJ shall have the right to convert any unpaid sums into common stock of the Company at the rate of the lesser of $.05 per share or 60% of the lowest trade reported in the 25 days prior to conversion. As of December 31, 2013, the Company received $50,000 of the note. During 2013, the Company recorded a discount of $50,000 on the note due to accounting for the conversion option as a derivative liability of which $1,849 was amortized during 2013.
	In February 2014, the Company entered into a 10% convertible note with Tangiers in the amount of $60,500. Of this amount, $5,500 was an original issue discount on the note. The note is amortized using the straight line method through the maturity date of February 27, 2015. The note is convertible at a variable price of the lower of $0.01 or 50% of the lowest trading price during the 25 day period prior to the date of conversion. The note is convertible 180 days from the date of the note. The note matures on February 27, 2015. In September 2014, the entire balance was converted into 8,066,666 shares of common stock using a conversion price of $0.0075 per share. The note was fully amortized since it was converted in full during the year 2014.
	In April 2014, the Company entered into a 12% Convertible Note with JSJ Investments, Inc. (“JSJ”) in the amount of $100,000.  Prior to October 28, 2014, the Company may redeem the Note for $150,000.  Thereafter, JSJ may convert the Note into common stock of the Company at a stated discount of 50% based on the average of the lowest three trades in the previous ten days, or $0.06 per share. The note matures on October 28, 2014.  The note was amended on October 21, 2014. The new conversion rate is now either 50% discount to the average of the three lowest trades in the previous ten days immediately prior to the date of conversion or a 50% discount to the average of the three lowest trades in the previous ten trading days immediately prior to October 28, 2014.  The new maturity date is April 28, 2015.  The amendment included a standstill provision whereby the parties agree to no conversions under the Note until February 1, 2015 and in consideration of the standstill provision the Company agrees to pay JSJ $36,000 by October 28, 2014, of which $1,000 is for legal fees payable to New Venture Attorneys, P.C. The payment of $35,000 to JSJ and payment of $1,000 to New Venture Attorneys, P.C. were both paid on October 27, 2014.
	In April 2014, the Company entered into an Equity Purchase Agreement and a Securities Purchase Agreement with Premier Venture Partners, LLC (“Premier”) whereby Premier is obligated, providing the Company has met certain conditions including the filing of a Form S-1 Registration Statement for the shares to be acquired, to purchase up to $5,000,000 of the Company’s common stock at the rates set forth at the request of the Company by issuing a Put Notice when funds are needed.  The Securities Purchase Agreement is a facility whereby the Company will receive $22,500 pursuant to two Convertible Promissory Notes.
	In April 2014, the Company entered into a Convertible Promissory note totaling $16,601 with ICPI for expense of rent of office space. ICPI may convert the note into fully paid and non-assessable shares of Series A Preferred Stock. The conversion price is $0.50 per share.
	In April 2014, the Company entered into a $10,000 Convertible Promissory Note (the “Note”) with Premier Venture Partners, LLC.  Under the terms of the Note the Company will receive $10,000 for the preparation and filing of the Form S-1 Registration Statement required for the Equity Purchase Agreement (Attached as Exhibit 99.02 to the Company's Form 8-K filed April 9, 2014). Premier Venture Partners, LLC shall have the right to convert any unpaid sums into common stock of the Company at the rate of the lesser of $.03 per share or 50% of the lowest trade reported in the 10 days prior to date of conversion.  A second Convertible Promissory Note, in the amount of $12,500, will be issued after the Form S-1 Registration Statement is filed in order to cover any additional expense of making the Form S-1 Registration Statement effective.  All of the $22,500 was paid directly to legal for the expense of preparing and making the S-1 Registrations Statement effective.
	In May 2014, the Company entered into a 10% Convertible Note with Typenex Co Investment LLC (“Typenex”) in the amount of $139,500, of which $14,500 is the original issue discount. The discount is amortized using the straight line method over the term of the note. Typenex may convert the Note into common stock of the Company at a conversion price of $0.07 per share. The note matures on March 28, 2015. In conjunction with the note, a total of 1,130,470 common stock warrants were issued. The warrants were accounted for as derivative liabilities resulting in a discount to the note of $83,682. In December 2014, $35,174 of the note and accrued interest was converted into 2,714,008 shares of common stock using a conversion price of $0.013 per share.
	In May 2014, the Company entered into an 8% Convertible Note with LG Capital Funding LLC (“LG”) in the amount of $58,500, of which $10,000 is the original issue discount.  The discount is amortized using the straight line method over the term of the note. LG may convert the Note into common stock of the Company at a stated discount of 50% based average of the lowest trading bid price for the 15 prior trading days. The note is convertible 180 days from the date of the note.
	In July 2014, the Company entered into a $200,000 Convertible Note with WHC Capital LLC, of which there is a $40,000 original issue discount. WHC was also issued 1,250,000 common shares as part of the agreement and those shares were recorded as debt discount of $52,500. WHC may convert the note into common stock of the Company at a 50% discount to the lowest trading price of 25 trading days prior to the conversion date. The note is convertible 180 days from the date of the note.  WHC was fully repaid in October of 2014 in the amount of $240,000.
	In July 2014, Tangiers provided additional funding to the Company in the amount of $50,000 in accordance with the February 2014 agreement.  The note had a $5,000 original issue discount and accrues interest at 10%.
	In August 2014, the Company entered into a 12% $100,000 Convertible Note with JSJ Investments. JSJ may convert the Note into common stock of the Company at a 50% discount to the average 3 lowest trading days of 20 trading days prior to conversion OR 20 trading days prior to the date the note was executed.
	In August 2014, the Company entered into a $56,250 Convertible Note with Auctus Private Equity Fund LLC, of which $6,250 is original issue discount. Auctus may convert the note into common stock at a 50% discount to the average 2 lowest trading days of 25 trading days prior to the conversion. The note is convertible 180 days from the date of the note.
	In September 2014, the Company entered into an amendment to the Tangiers convertible note up to the amount of $220,000 from February 2014.   Company borrowed a total of $55,000 of which $5,000 is original issue discount. Tangiers may convert the Note into common stock of the Company at the lower of $0.023 or a 50% discount to the trading price of the prior 25 trading days. The note is convertible 180 days from the date of the note.  The new term of the note is September 22, 2014.
	In September 2014, JMJ Investments provided additional funding to the Company in the amount of $50,000 in accordance with the December 2013 agreement of which $5,556 is original issue discount.
	In September 2014, the Company entered into a $55,250 Convertible Note with Auctus Private Equity Fund LLC, of which $5,250 is original issue discount. Auctus may convert the note into common stock at a 50% discount to the average 2 lowest trading days of 25 trading days prior to the conversion. The note is convertible 180 days from the date of the note.
	In October 2014, the Company entered into a 8% Convertible Note with Union Capital LLC in the amount of $50,000 of which $2,500 is original issue discount. Union may convert the note into common shares of the Company at a discount of 50% to the lowest trading price of the 20 trading days prior to the conversion date.
	In October 2014, the Company entered into a $55,000 Convertible Note with Vista Capital Investments LLC, of which $6,111 is original issue discount. Vista may convert the note into common shares of the Company at $0.05 or a 60% discount to the lowest trading price of the 25 days prior to the conversion date.
	In October 2014, JMJ Investments provided additional funding to the Company in the amount of $40,000 in accordance with the December 2013 agreement of which $4,444 is original issue discount.
	In October 2014, the Company entered into a 8% Convertible Note with LG Capital Funding LLC in the amount of $47,250, of which $6,750 is original issue discount. LG may convert the note into common shares of the Company at a 50% discount to the lowest trading price of the 15 days prior to the conversion date.
	In October 2014, the Company entered into a 10% Convertible Note with Sarna Family Limited Partnership in the amount of $200,000. Sarna may convert the note into common shares of the Company at $0.01. In November 2014, $25,000 of the note was converted into 2,500,000 shares of common stock using a conversion price of $0.01 per share.
	In October 2014, the Company entered into a 10% Convertible Note with private investor Mark Sarna in the amount of $200,000. Mr. Sarna may convert the note into common shares of the Company at $0.01. In November 2014, $25,000 of the note was converted into 2,500,000 shares of common stock using a conversion price of $0.01 per share.
	In October 2014, the Company paid off the WHC Capital LLC Convertible Note in the amount of $240,000.
	In October 2014, the Company entered into a 10% Convertible Note with Macallan Partners in the amount of $110,000, of which $10,000 is original issue discount.  Macallan may convert the note into common shares of the Company at the lesser of a 50% discount to the lowest price in the previous 20 days prior to conversion or at a 50% discount to the bid price on the day of conversion.
	In November 2014, the Company entered into a 12% Convertible Note with Eastmore Capital in the amount of $55,000, of which $4,000 is original issue discount. Eastmore may convert the note into common shares of the Company at the lesser of the lowest trading price of the day preceding the conversion or at a 50% discount to the lowest price in the previous 15 trading days before the conversion.
	In November 2014, the Company entered into a 12% Convertible Note with Carebourn Capital in the amount of $128,000, of which $15,800 is original issue discount.  Carebourn may convert the note into common shares of the Company at a discount of 50% of the average 3 lowest trading days within the previous 10 trading days prior to conversion.
	In December 2014, the Company entered into a 10% Convertible Note with SBI Investments in the amount of $240,000, of which $40,000 is original issue discount. SBI may convert the note into common shares of the Company at a 50% discount to the lowest trading price in the previous 25 trading days prior to the conversion.
	In December 2014, the Company entered into a 10% Convertible Note with investor Joshua Parkiel in the amount of $12,500. Mr. Parkiel may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with private investor David Sarna in the amount of $12,500. Mr. Sarna may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with investor Howard Schwartz in the amount of $25,000. Mr Schwartz may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with private investor Larry Pantirer in the amount of $25,000. Mr. Pantirer may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with investor Seymour Pinewski in the amount of $50,000. Mr Pinewski may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with private investor Stuart Troyetsky in the amount of $50,000. Mr. Troyetsky may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with investor Alan Pines in the amount of $75,000. Mr Pines may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with private investor Martin Statfield in the amount of $50,000. Mr. Statfield may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with investor Morris Sarna in the amount of $50,000. Mr. Sarna may convert the note into common shares of the Company at $0.01.
	In December 2014, the Company entered into a 10% Convertible Note with private investor Steve Montag in the amount of $12,500. Mr. Montag may convert the note into common shares of the Company at $0.01.
	In 2014, JMJ Investments converted an aggregate of $62,169 of notes and accrued interest into 5,330,247 shares of common stock using conversion prices ranging from $0.0075 to $0.204 per share.
	Aggregate amortization of debt discounts totaled $635,273. As of December 31, 2014, the unamortized debt discounts totaled $1,197,566.
	The Company evaluated all convertible notes describe above under ASC 815 and determined that they qualify as derivative liabilities (see Note 6).
	Future minimum payments owed on the outstanding debt, including accrued interest, of the Company as of December 31, 2014 are as follows:
		Year Ended December 31,
		2015			2016			2017			2018		2019		Total
	Convertible Notes		1,346,746			103,210			-			-		717,411		2,167,367
	Short-term Non-Convertible Note		4,557			-			-			-		-		4,557
Total		1,351,303			103,210			-			-		717,411		2,171,924

Note_6Derivative_Liabiliities

Note 6-Derivative Liabiliities	12 Months Ended
	Dec. 31, 2014
Notes
Note 6-Derivative Liabiliities	Note 6—DERIVATIVE LIABILIITIES
	The Company evaluates all of it financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
	Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
	Under ASC-815 the conversion options embedded in the notes payable described in Note 5 require liability classification because they do not contain an explicit limit to the number of shares that could be issued upon settlement. In addition, all of the Company’s outstanding common stock warrants are tainted in 2013 and 2014 and accounted for as derivative liabilities.
	The following table summarizes the changes in the derivative liabilities during 2013 and 2014:
	Balance as of December 31, 2012	$	-
	Additions at fair value recognized as expense		131,459
	Additions at fair value recognized as debt discounts		50,000
	Gain on change in fair value		-9,410
	Balance as of December 31, 2013	$	172,049
	Additions at fair value recognized as expense		2,310,191
	Additions at fair value recognized as debt discounts		1,556,574
	Gain on change in fair value		-1,017,772
	Resolution of derivative liabilities		-445,017
	Balance as of December 31, 2014	$	2,576,025
	During 2014 and 2013, the aggregate loss on derivative liabilities was $1,292,419 and $122,049, respectively, consisting of initial derivative expense and the change in the fair value of the derivative liabilities.
	The Company uses the Black Scholes Option Pricing Model to value its convertible debt and warrant derivative liabilities based upon the following assumptions:
		2013			2014
	Dividend yield:		0	%		0	%
	Expected volatility		207.8	%	145.0% to 243.0		%
	Risk free interest rate		0.38	%	.03% to 1.65		%
	Expected life (years)		1.95		0.13 to 5.05

Note_7Income_Taxes

Note 7-Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
Note 7-Income Taxes	Note 7—INCOME TAXES
	The Company uses the liability method, where deferred tax assets and liabilities are determined based on the expected future tax consequences of temporary differences between the carrying amounts of assets and liabilities for financial and income tax reporting purposes. During 2013 and 2014, the company incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. The cumulative net operating loss carry-forward is approximately $3,500,000 at December 31, 2014, and will expire in the years 2031 – 2033.
	Internal Revenue Section 382 restricts the ability to use these carryforwards whenever an ownership change as defined occurs.
	At December 31, 2014, deferred tax assets consisted of the following:
	Deferred tax assets
	Net operating losses	$	1,226,720
	Less: valuation allowance		(1,226,720	)
	Net deferred tax asset	$	-
	At December 31, 2013, deferred tax assets consisted of the following:
	Deferred tax assets
	Net operating losses	$	767,134
	Less: valuation allowance		-767,134
	Net deferred tax asset	$	-

Note_8Loans_Payable

Note 8-Loans Payable	12 Months Ended
	Dec. 31, 2014
Notes
Note 8-Loans Payable	Note 8—LOANS PAYABLE
	In June 2013 Pazoo, Inc. entered into a Promissory note totaling $9,000 with ICPI for expenses paid directly to vendors.  In November 2013, $6,000 was converted into 15,000 Series A Preferred shares.  ICPI is a Series A Preferred stockholder.  As of December 31, 2014 and 2013, $3,000 still remains outstanding.

Note_9Subsequent_Events

Note 9-Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes
Note 9-Subsequent Events	Note 9—SUBSEQUENT EVENTS
	In January 2015, Premier Ventures, LLC, purchased 5,460,125 common shares for $48,380 pursuant to the put option executed by the Company.
	In January 2015, ICPI converted 130,000 Series A Preferred shares into 13,000,000 common shares.

Note_1Description_of_Business_1

Note 1-Description of Business and Significant Accounting Policies: Description of Business (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Description of Business	Description of Business
	We were incorporated as a C-Corporation in the State of Nevada as IUCSS, Inc. on November 16, 2010 and we established a fiscal year end of December 31. On May 9, 2011, we changed our name to Pazoo, Inc. to take advantage of unique branding and website opportunities. We are a start-up health and wellness social community that has developed its website (www.pazoo.com) to provide information, services, and online products for improvement of everyday living. Our mission is to be 1) a leading social community offering best-in-class health and wellness products for both people and pets; and 2) an important resource for consumers and professionals with diverse information about health and wellness. We have never been party to any bankruptcy, receivership or similar proceeding, nor have we undergone any material reclassification, merger, consolidation, purchase or sale of a significant amount of assets not in the ordinary course of business.

Note_1Description_of_Business_2

Note 1-Description of Business and Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Use of Estimates	Use of Estimates
	In accordance with Generally Accepted Accounting Principles (GAAP) the preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period.
	On an ongoing basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described at relevant sections in the notes to the financial statements.

Note_1Description_of_Business_3

Note 1-Description of Business and Significant Accounting Policies: Equity Method Investments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Equity Method Investments	Equity Method Investments
	Equity method investees are all entities over which the Company has significant influence, but not control. Significant influence is presumed with a shareholding of between 20% and 50% of the voting rights. Investments in equity method investees are accounted for using the equity method of accounting and are initially recognized at cost. As of December 31, 2014, the Company has investments in, MA & Associates, LLC and Harris Lee, LLC which provide the Company with significant influence.
	On April 8, 2014 the Company entered into a Limited Liability Company Membership Interest Purchase Agreement with MA & Associates, LLC (“MA”) under which the Company agreed to acquire a 40% equity interest in MA for two testing locations in exchange for a purchase price of $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock. MA was formed to become a marijuana testing laboratory within the State of Nevada. As set forth in the Purchase Agreement, the Purchase Price is to be paid to MA in accordance with certain milestones including the approval of a State License to become a testing laboratory, laboratory build out milestones, and testing equipment purchases.  In 2014 the Company paid an aggregate of $542,780 of the cash portion of the purchase price consisting of an investment of $542,780. As of December 31, 2014, the Company owned an approximate 22% interest in MA and had the right to appoint one of four Board members of MA. This equity method investment was fully impaired during 2014. In 2015, the Company paid an additional $605,000 of the $2,000,000 cash portion of the purchase price and issued 100,000 of the 150,000 shares to be issued with the remaining shares being issued after the testing laboratory is operational.  A copy of the Purchase Agreement is attached as Exhibit 99.01 to the Form 8-K filed by the Company on April 9, 2014.
	On July 23, 2014, the Company and the MA founders formed Harris Lee Holdings, LLC (“Harris Lee”) of which the Company obtained a 45% equity interest for an initial cash contribution of $45.  On October 24, 2014, the Company agreed to acquire an additional 10% interest in Harris Lee in exchange for 300,000 shares of the Company’s Series C Preferred stock based on a series of milestone events. As of December 31, 2014, the acquisition of this additional 10% interest had not closed. Then on January 13, 2015, the Company agreed to acquire the remaining 45% of Harris Lee in exchange for 450,000 shares of the Company’s Series B Preferred Stock, again issued upon completion of certain milestones.  No construction has commenced on any Harris Lee facility and accordingly no cash has been paid to date.  No shares were issued in 2014. In 2015, based on the milestones, 150,000 shares of Series C Preferred Stock were issued, and all of the 450,000 shares of Series B Preferred Stock were issued.
	The Company recognizes its share of the net income or losses for MA and Harris Lee in the Statements of Operations, after adjustments to align the accounting policies with those of the Company, from the date that significant influence commences until the date that significant influence ceases. When the Company’s share of losses exceeds its interest in an equity method investees, the carrying amount of that interest (including any long-term loans) is reduced to zero and recognition of further losses is discontinued except to the extent that the  Company has incurred legal or constructive obligations or made payments on behalf of the equity method investees. Unrealized gains on transactions between the Company and its equity method investees are eliminated to the extent of the Company’s interest in the equity method investees. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Re-measurement differences of equity stake resulting from gaining control over the investee previously recorded as an equity method investments are recorded under Results related to investments in equity method investees. During the year ended December 31, 2014, aggregate equity method investment losses recognized was zero as it was determined to be nominal.
	During the year ended December 31, 2014, the Company performed an impairment analysis and determined that due to the fact that MA is a start up with no current cash flows; we impaired 100% of the equity method investment resulting in an impairment loss of $542,780 during 2014.

Note_1Description_of_Business_4

Note 1-Description of Business and Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The Company’s financial instruments consist principally of cash and cash equivalents and accounts payable. The Company believes that the recorded values of all of its other financial instruments approximate their fair values because of their nature and respective maturity dates or durations. The fair value of our long-term debt is determined by using estimated market prices. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:
	Level 1: Inputs are based on quoted market prices for identical assets or liabilities in active markets at the measurement date.
	Level 2: Inputs include quoted prices for similar assets or liabilities in active markets and/or quoted prices for identical or similar assets or liabilities in markets that are not active near the measurement date.
	Level 3: Inputs include management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value as December 31, 2014 and 2013.
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability – December 31, 2014	$	-	$	-	$	2,576,025	$	2,576,025
	Derivative liability – December 31, 2013	$	-	$	-	$	172,049	$	172,049

Note_1Description_of_Business_5

Note 1-Description of Business and Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents
	We classify all highly liquid instruments with an original maturity of three months or less at the time of purchase as cash equivalents.

Note_1Description_of_Business_6

Note 1-Description of Business and Significant Accounting Policies: Stock Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Stock Based Compensation	Stock Based Compensation
	Total stock-based compensation recognized during 2014 and 2013 totaled $1,116,008 consisting of 35,374,269 common shares and 15,000 Series A preferred shares and $96,128 consisting of 2,517,500 common shares, respectively.  ASC 718 "Compensation - Stock Compensation" prescribes accounting and reporting standards for all stock-based payments awarded to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, which may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction is recognized as a liability; otherwise, the transaction is recognized as equity.  The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50 "Equity-Based Payments to Non-Employees." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date, the performance completion date, or the contract date.

Note_1Description_of_Business_7

Note 1-Description of Business and Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Revenue Recognition	Revenue Recognition
	Revenues are recognized when evidence of an agreement exists, the price is fixed or determinable, collectability is reasonably assured and goods have been delivered or services performed.  The Company is paid revenue from various advertising sources.  Typically advertising revenue is based upon the activity reports received from the advertising brokers and revenue is paid in accordance with the broker agreements at varying intervals from 30 to 75 days following the close of the particular advertising period.  The Company recognizes the revenue, and records the accounts receivable, upon receipt of the activity report from the broker.  In the event payment is not received within 120 days of the due date, the Company with classify such amount as an account where collection is doubtful.  At this time the Company has no reason to believe any accounts are not collectible and therefore no allowance for doubtful accounts has been made at this time for any advertising revenue.

Note_1Description_of_Business_8

Note 1-Description of Business and Significant Accounting Policies: Inventories (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Inventories	Inventories
	Inventory currently consists predominately of goods purchased from third party suppliers and does not include raw materials. Certain inventory contains expiration dates (“shelf life”) and the efficacy of any product which is held beyond its shelf life may be impaired. Our inventory reserve is zero. The company purchased most inventory in 2011 with very little purchases in 2012 and as such, there are some products that are approaching the end of their shelf life and were written off in 2013 and 2014. Inventory cost is determined using the weighted average cost method.

Note_1Description_of_Business_9

Note 1-Description of Business and Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Income Taxes	Income Taxes
	Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse.
	We have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that we will not realize a future tax benefit, a valuation allowance is established.

Recovered_Sheet1

Note 1-Description of Business and Significant Accounting Policies: Basic and Diluted Net Loss Per Common Share (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share
	Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share reflects, in addition to the weighted average number of common shares, the potential dilution if shares of convertible preferred stock were converted into shares of common stock and a corresponding accrued 5% dividend, unless the effects of such exercises and conversions would have been anti-dilutive.

Recovered_Sheet2

Note 1-Description of Business and Significant Accounting Policies: Recent Accounting Pronouncements (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	The Company does not expect any recently issued accounting pronouncements to have a material impact on its financial condition or results of operations.

Note_3Stockholders_Equity_Pref

Note 3-Stockholders' Equity: Preferred Stock (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Preferred Stock	Preferred Stock
	We have authorized 20 million shares of $0.001 par value Preferred Stock. The preferred shares available for issuance are 10,000,000 Series A Convertible Preferred Stock, 2,500,000 Series B Non-convertible Preferred Stock, and 7,500,000 Series C Non-convertible Preferred Stock.
	The Series A Preferred Stock is convertible into ten shares of common stock for each Preferred share at the option of the holder, does not have voting rights and pays a Series A Preferred Stock dividend of 5% annually. The Company amended the Certificate of Designations of the Series A Preferred Stock amending the expiration date to February 1, 2022. The Company shall pay the amount due on the Maturity Date in kind with shares of Common Stock. The number of shares of Common Stock to be issuable to a Holder on the Maturity Date (the “Maturity Shares”) shall be equal to the quotient of (x) the aggregate Liquidation Preference for such Holder’s Shares on the Maturity Date divided by (y) the Conversion Price in effect as of the Maturity Date. On or before the third (3rd) Business Day following the Maturity Date (the “Maturity Share Delivery Date”), the Company must deliver to each Holder the Maturity Shares issuable to such Holder. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to (A) $1,000 per Share held by such Holder, plus (B) a further amount equal to any Dividends accrued but unpaid on such Shares. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be appropriately adjusted for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	The Series B Preferred Stock is non-convertible, does not pay a dividend, and contains voting rights at a ratio of 200 votes for each share of Series B Preferred Stock. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to $0.001 per Share held by such Holder, or such other amount as any Securities Purchase Agreement under which the Shares are issued may provide. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be unaffected for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	The Series C Preferred Stock is non-convertible and has no voting rights, pays a common stock dividend from 2% to 12% annually. The Company amended the Certificate of Designations of the Series C Preferred Stock amending the expiration date for redemption to February 1, 2022. The Company shall pay the amount due on the Maturity Date in kind with shares of Common Stock. The number of shares of Common Stock to be issuable to a Holder on the Maturity Date (the “Maturity Shares”) shall be equal to the quotient of (x) the aggregate Liquidation Preference for such Holder’s Shares on the Maturity Date divided by (y) the Conversion Price in effect as of the Maturity Date. On or before the third (3rd) Business Day following the Maturity Date (the “Maturity Share Delivery Date”), the Company must deliver to each Holder the Maturity Shares issuable to such Holder. In the event of any liquidation, dissolution or winding up of the Company, either voluntarily or involuntarily, each Holder shall be entitled to receive prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of any Junior Stock, an amount (the “Liquidation Preference”) equal to (A) $0.001per Share held by such Holder, plus (B) a further amount equal to any Dividends accrued but unpaid on such Shares. If, upon such liquidation, dissolution or winding up of the Company, the assets of the Company available for distribution to the stockholders of the Company are insufficient to provide for the payment of the full aforesaid preferential amount, such assets as are so available shall be distributed among the Holders in proportion to the relative aggregate Liquidation Preferences of the Shares held by such Holders. The Liquidation Preference shall be appropriately adjusted for any stock splits, stock combinations, stock dividends or similar recapitalizations.
	In May 2013, we exchanged 136,058 Series A Preferred Stock and 136,058 Series A Preferred stock warrants to Integrated Capital Partners, Inc. (ICPI) for the conversion of $54,423 in loans payable.
	Also, in November 2013, we exchanged 1,774 Series A Preferred Stock and 1,774 Series A Preferred stock warrants to ICPI for $710 in loans payable.
	During 2013, the Company sold an aggregate of 487,168 shares of Series A Preferred Stock and 487,168 Series A Preferred stock warrants for cash proceeds of $194,867.
	In December 2013, we recorded a preferred stock dividend of 31,612 shares of Series A Preferred Stock valued at $66,701 which represents payment of the 5% stated Series A Convertible Preferred Stock dividend (through December 31, 2013).
	In August 2013, 187,500 Series B Preferred shares were sent back to the Company and cancelled for David Cunic, who stepped down as Chairman of the Board in 2012.
	During 2013, 287,500 shares of Series A preferred stock were converted into 28,750,000 common shares.
	Total Series A Preferred shares outstanding as of December 31, 2013 were 923,394.
	On or about March 17, 2014, the Board of Directors voted to affect a 10 for 1 reverse stock split on all outstanding Series A Preferred Stock. All share and per share amounts herein have been retroactively restated to reflect the split.
	On or about April 8, 2014 the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the “Purchase Agreement”) with MA and Associates, LLC (“MA”) whereby the Company will acquire a 40% equity interest in MA in exchange for $2,000,000 and 150,000 shares of the Company’s Series C Preferred Stock.  The Company will complete its due diligence by April 30, 2014 and the closing will occur following the Company’s satisfaction of its due diligence.  MA is in the process of setting up two licensed marijuana testing facilities in the State of Nevada. No shares were issued during the year ended December 31, 2014.
	In 2014, The Company sold an aggregate of 287,500 of Series A Preferred Stock and 287,500 Series A preferred stock warrants for cash proceeds of $340,000.
	In 2014, ICPI exercised warrants in the amount of 80,000 Series A Preferred Stock warrants for cash proceeds of $40,000
	In August 2014, 10,000 shares of Series A Preferred Stock was issued to Jordan Stroum as Pazoo’s representative to MA & Associates in Las Vegas, Nevada per the agreement signed July 25, 2014. Series A Preferred Stock converts at a rate of 100:1. The 10,000 Series A Preferred Stock convert into 1,000,000 shares of common stock. The shares were valued at $34,800.
	In October 2014, 5,000 Series A Preferred Stock was issued to Jordan Stroum in exchange for services rendered as Pazoo’s representative to MA & Associates in Las Vegas, Nevada as per the agreement signed July 25, 2014.  Series A Preferred Stock converts at a rate of 100:1.  The 10,000 Series A Preferred Stock convert into 1,000,000 shares of common stock. The shares were valued at $19,850.
	During 2014, 269,500 shares of Series A preferred stock were converted into 26,950,000 common shares.
	Total Series A Preferred shares outstanding as of December 31, 2014 were 1,036,394.

Note_3Stockholders_Equity_Comm

Note 3-Stockholders' Equity: Common Stock (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Common Stock	Common Stock
	Issuances
	In 2013, we issued a total of 2,517,500 common shares to experts who have agreed to be included in the “Our Experts” section of our Company website (www.pazoo.com). Each Expert has executed an expert services contract certain number of shares issued upon signing and further shares earned over the first year of the contract. The total stock compensation expense recorded during 2013 was $96,128. As of December 31, 2013, there were 2,815,000 shares to be issued that will be earned through 2014.
	In April 2013, we cancelled 2,000,000 common shares previously issued to Gotham Capital for an advisory agreement 2012.
	In 2014, we issued a total of 5,196,117 common shares for aggregate cash proceeds of $77,076, in accordance with the put agreements per the equity agreement with Premier Venture Capital dated April 4, 2014.
	In 2014, we issued a total of 1,739,591 common shares for a stock subscription receivable $18,253 which was collected during 2015.
	In 2014, we issued a total of 35,374,269 common shares to consultants and experts who have agreed to be included in the “Our Experts” section of our Company website (www.pazoo.com) as well as certain consultants.  Each expert has executed an expert services contract giving them a certain number of shares issued upon the signing of the agreement and further shares on each anniversary of the contract date. Consultants were used by the Company to increase its marketing, advertising, and awareness. Consultants were issued shares based on individual service contracts. The total stock compensation expense recorded during 2014 was $1,061,358. As of December 31, 2014, there were 5,893,333 shares to be issued that will be earned through 2015.
	In 2014, we issued 1,250,000 common shares with debt valued and recorded as a debt discount at $35,897.
	Conversions
	In 2014, we issued an aggregate of 21,110,921 common shares for the conversion of debt and accrued interest totaling $207,843.

Note_3Stockholders_Equity_Warr

Note 3-Stockholders' Equity: Warrants (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Warrants	Warrants
	Simultaneous with the issuance of Series A Preferred Stock in 2013, and under the Investment Agreement May 2013 we issued 623,226 warrants to ICPI which entitles its owner to purchase one share of Series A Preferred Stock for each Series A Preferred Stock at an exercise price of $0.50, subject to the terms of the warrant agreement between the warrant agent and us. The warrants are exercisable three years from the date of issue. No warrants have been exercised as of December 31, 2013. These warrants had negligible fair value at the time of issuance.
	In connection with a termination and release agreement on or about April 2013, and related to compensation paid to Gotham Capital (Gotham) in 2012, we cancelled 2,000,000 common stock purchase warrants exercisable at an exercise price of $0.01 per share.
	In 2014, ICPI exercised 80,000 Series A Preferred Stock warrants for cash proceeds of $40,000
	In 2014, The Company sold an aggregate of 287,500 of Series A Preferred Stock and 287,500 Series A preferred stock warrants for cash proceeds of $340,000.
	The following table presents the Series A preferred stock warrant activity during 2014 and 2013:
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		200,000	$	7.5
	Granted		623,226	$	0.5
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		287,000		2.18
	Forfeited/canceled		-80,000		0.5
	Exercised		-		-
	Outstanding - December 31, 2014		1,030,226	$	2.23
	Exercisable – December 31, 2014		1,030,226	$	2.23
	The weighted average remaining life of the outstanding Series A preferred stock warrants as of December 31, 2014 and 2013 was 3.26 and 3.92 years, respectively.
	The following table presents the common stock warrant activity during 2014 and 2013:
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		7,000,000	$	0.05
	Granted		-		-
	Forfeited/canceled		-2,000,000		0.05
	Exercised		-		-
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		1,130,470		0.05
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding – December 31, 2014		6,130,470	$	0.05
	Exercisable – December 31, 2014		6,130,470	$	0.05
	The weighted average remaining life of the outstanding Series A common stock warrants as of December 31, 2014 and 2013 was 0.48 and 1.26 years, respectively.

Recovered_Sheet3

Note 1-Description of Business and Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
	Recurring Fair Value Measurements	Level 1		Level 2		Level 3		Total
	LIABILITIES:
	Derivative liability – December 31, 2014	$	-	$	-	$	2,576,025	$	2,576,025
	Derivative liability – December 31, 2013	$	-	$	-	$	172,049	$	172,049

Note_3Stockholders_Equity_Warr1

Note 3-Stockholders' Equity: Warrants: Schedule of Preferred Units (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Preferred Units
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		200,000	$	7.5
	Granted		623,226	$	0.5
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding - December 31, 2013		823,226	$	2.2
	Granted		287,000		2.18
	Forfeited/canceled		-80,000		0.5
	Exercised		-		-
	Outstanding - December 31, 2014		1,030,226	$	2.23
	Exercisable – December 31, 2014		1,030,226	$	2.23

Note_3Stockholders_Equity_Warr2

Note 3-Stockholders' Equity: Warrants: Schedule of Stockholders' Equity Note, Warrants or Rights (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Stockholders' Equity Note, Warrants or Rights
				Weighted
				Average
		Warrants		Exercise Price
	Outstanding - December 31, 2012		7,000,000	$	0.05
	Granted		-		-
	Forfeited/canceled		-2,000,000		0.05
	Exercised		-		-
	Outstanding - December 31, 2013		5,000,000	$	0.05
	Granted		1,130,470		0.05
	Forfeited/canceled		-		-
	Exercised		-		-
	Outstanding – December 31, 2014		6,130,470	$	0.05
	Exercisable – December 31, 2014		6,130,470	$	0.05

Note_5Convertible_Notes_Conver

Note 5-Convertible Notes: Convertible Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Convertible Debt
		Short Term			Long Term			Total
	Balance as of December 31, 2012	$	-		$	-		$	-
	Cash additions		50,000			-			50,000
	Non-cash additions					-			-
	Cash payments		-			-			-
	Conversions		-			-			-
	Original issue discount		-			-			-
	Total		50,000			-			50,000
	Less:  unamortized discount		(48,151	)		-			(48,151	)
	Balance as of December 31, 2013	$	1,849		$	-		$	1,849
	Cash additions		1,444,700			852,500			2,297,200
	Non-cash additions		16,601			-			16,601
	Cash payments		(240,000	)		-			(240,000	)
	Conversions		(88,400	)		(50,000	)		(138,400	)
	Original issue discount		176,661			10,000			186,661
	Total		1,309,562			812,500			2,122,062
	Less:  unamortized discount		(413,898	)		(783,668	)		(1,197,566	)
	Balance as of December 31, 2014	$	895,664		$	28,832		$	924,496

Note_5Convertible_Notes_Schedu

Note 5-Convertible Notes: Schedule of Maturities of Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Maturities of Long-term Debt
		Year Ended December 31,
		2015		2016		2017		2018		2019		Total
	Convertible Notes		1,346,746		103,210		-		-		717,411		2,167,367
	Short-term Non-Convertible Note		4,557		-		-		-		-		4,557
	Total		1,351,303		103,210		-		-		717,411		2,171,924

Note_6Derivative_Liabiliities_

Note 6-Derivative Liabiliities: Schedule of Derivative Liabilities at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Derivative Liabilities at Fair Value
	Balance as of December 31, 2012	$	-
	Additions at fair value recognized as expense		131,459
	Additions at fair value recognized as debt discounts		50,000
	Gain on change in fair value		-9,410
	Balance as of December 31, 2013	$	172,049
	Additions at fair value recognized as expense		2,310,191
	Additions at fair value recognized as debt discounts		1,556,574
	Gain on change in fair value		-1,017,772
	Resolution of derivative liabilities		-445,017
	Balance as of December 31, 2014	$	2,576,025

Note_6Derivative_Liabiliities_1

Note 6-Derivative Liabiliities: Schedule of Interest Rate Derivatives (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Interest Rate Derivatives
		2013			2014
	Dividend yield:		0	%		0	%
	Expected volatility		207.8	%	145.0% to 243.0		%
	Risk free interest rate		0.38	%	.03% to 1.65		%
	Expected life (years)		1.95		0.13 to 5.05

Note_7Income_Taxes_Schedule_of

Note 7-Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities
	At December 31, 2014, deferred tax assets consisted of the following:
	Deferred tax assets
	Net operating losses	$	1,226,720
	Less: valuation allowance		(1,226,720	)
	Net deferred tax asset	$	-
	At December 31, 2013, deferred tax assets consisted of the following:
	Deferred tax assets
	Net operating losses	$	767,134
	Less: valuation allowance		-767,134
	Net deferred tax asset	$	-

Recovered_Sheet4

Note 1-Description of Business and Significant Accounting Policies: Equity Method Investments (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Details
Loss on impairment of equity method investment	$542,780

Note_2Going_Concern_Details

Note 2-Going Concern (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Net loss	$4,899,583	$657,690
Capital	$2,757,052

Note_3Stockholders_Equity_Pref1

Note 3-Stockholders' Equity: Preferred Stock (Details) (USD $)	Dec. 31, 2014
Details
Preferred Stock, Par Value	$0.00

Note_4Related_Party_Transactio1

Note 4-Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Professional and Contract Services Expense	$57,650	$14,750

Note_6Derivative_Liabiliities_2

Note 6-Derivative Liabiliities (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Loss on derivative liabilities	$1,292,419	$122,049